Is smaller better?Vaccine targeting recombinant receptorbinding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic

A recent report by Yang et al.published in Nature reported a recombinant vaccine utilizing recombinant receptor-binding domain(RBD)of SARS-CoV-2 Spike Protein.1 This vaccine candidate successfully induced potent functional antibody responses in the immunized mice,rabbits,and non-human primates.The study highlights the critical role of the immunogenicity of the RBD domain upon SARS-CoV-2 infection and the alternate vaccine designs that could serve as effective prophylactics against the pandemic.